Targeting VEGFR-3/-2 signaling pathways with AD0157: a potential strategy against tumor-associated lymphangiogenesis and lymphatic metastases

[1]  A. Ravaud.  Adjuvant Sunitinib in Renal-Cell Carcinoma. , 2017, The New England journal of medicine.

[2]  T. Yeh,et al.  Surgical management of patients with progressing metastatic gastrointestinal stromal tumors receiving sunitinib treatment: A prospective cohort study. , 2017, International journal of surgery.

[3]  Lai-han Leung,et al.  Efficacy and safety of angiogenesis inhibitors in advanced gastric cancer: a systematic review and meta-analysis , 2016, Journal of Hematology & Oncology.

[4]  F. Du,et al.  Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors , 2016, Journal of Hematology & Oncology.

[5]  M. Saif,et al.  Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer , 2016, Cancer Chemotherapy and Pharmacology.

[6]  M. Martín,et al.  Review: circulating tumor cells in the practice of breast cancer oncology , 2016, Clinical and Translational Oncology.

[7]  A. Noël,et al.  Novel application assigned to toluquinol: inhibition of lymphangiogenesis by interfering with VEGF‐C/VEGFR‐3 signalling pathway , 2016, British journal of pharmacology.

[8]  Roman Paduch,et al.  The role of lymphangiogenesis and angiogenesis in tumor metastasis , 2016, Cellular Oncology.

[9]  T. Watabe,et al.  Roles of signaling and transcriptional networks in pathological lymphangiogenesis. , 2016, Advanced drug delivery reviews.

[10]  M. Detmar,et al.  Tumor lymphangiogenesis and new drug development. , 2016, Advanced drug delivery reviews.

[11]  J. Sleeman.  The lymph node pre-metastatic niche , 2015, Journal of Molecular Medicine.

[12]  S. Burrows,et al.  Retrospective preoperative assessment of the axillary lymph nodes in patients with breast cancer and literature review. , 2015, Clinical radiology.

[13]  G. Mazzucchelli,et al.  Blocking lipid synthesis overcomes tumor regrowth and metastasis after antiangiogenic therapy withdrawal. , 2014, Cell metabolism.

[14]  Walter L Murfee,et al.  VEGF‐C Induces Lymphangiogenesis and Angiogenesis in the Rat Mesentery Culture Model , 2014, Microcirculation.

[15]  Eric Bullinger,et al.  Cell Invasion in the Spheroid Sprouting Assay: A Spatial Organisation Analysis Adaptable to Cell Behaviour , 2014, PloS one.

[16]  S. Stacker,et al.  Lymphangiogenesis and lymphatic vessel remodelling in cancer , 2014, Nature Reviews Cancer.

[17]  Fan Wang,et al.  Ethyl pyruvate inhibits proliferation and induces apoptosis of hepatocellular carcinoma via regulation of the HMGB1-RAGE and AKT pathways. , 2014, Biochemical and biophysical research communications.

[18]  M. Medina,et al.  The Marine Fungal Metabolite, AD0157, Inhibits Angiogenesis by Targeting the Akt Signaling Pathway , 2014, Marine drugs.

[19]  G. Dionigi,et al.  Prognostic role of micrometastases in sentinel lymph node in patients with invasive breast cancer. , 2013, International journal of surgery.

[20]  J. Rakic,et al.  Sunitinib inhibits inflammatory corneal lymphangiogenesis. , 2013, Investigative ophthalmology & visual science.

[21]  A. Sood,et al.  Targeted Silencing of Elongation Factor 2 Kinase Suppresses Growth and Sensitizes Tumors to Doxorubicin in an Orthotopic Model of Breast Cancer , 2012, PloS one.

[22]  V. Lambert,et al.  Matrix metalloproteinase-2 governs lymphatic vessel formation as an interstitial collagenase. , 2012, Blood.

[23]  P. Rutkowski,et al.  The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study , 2012, BMC Cancer.

[24]  K. Alitalo,et al.  The lymphatic vasculature in disease , 2011, Nature Medicine.

[25]  R. Kerbel.  Reappraising antiangiogenic therapy for breast cancer. , 2011, Breast.

[26]  Miguel Martín.  Understanding the value of antiangiogenic therapy in metastatic breast cancer , 2011, Current opinion in oncology.

[27]  M. Flister,et al.  Lymphangiogenesis and lymphatic metastasis in breast cancer. , 2010, Pathophysiology : the official journal of the International Society for Pathophysiology.

[28]  S Blacher,et al.  Additional parameters for the morphometry of angiogenesis and lymphangiogenesis in corneal flat mounts. , 2009, Experimental eye research.

[29]  Masahiro Inoue,et al.  Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. , 2009, Cancer cell.

[30]  J. Wood,et al.  Differential effects of the vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 on tumor angiogenesis and tumor lymphangiogenesis , 2009, Molecular Cancer Therapeutics.

[31]  K. Alitalo,et al.  Suppression of prostate cancer nodal and systemic metastasis by blockade of the lymphangiogenic axis. , 2008, Cancer research.

[32]  Y. Funahashi,et al.  Multi-Kinase Inhibitor E7080 Suppresses Lymph Node and Lung Metastases of Human Mammary Breast Tumor MDA-MB-231 via Inhibition of Vascular Endothelial Growth Factor-Receptor (VEGF-R) 2 and VEGF-R3 Kinase , 2008, Clinical Cancer Research.

[33]  K. Alitalo,et al.  The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. , 2008, Cancer research.

[34]  P. Carmeliet,et al.  Modeling lymphangiogenesis in a three-dimensional culture system , 2008, Nature Methods.

[35]  G. F. Wagner,et al.  COX-2-mediated stimulation of the lymphangiogenic factor VEGF-C in human breast cancer , 2006, British Journal of Cancer.

[36]  M. Skobe,et al.  Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2. , 2006, Cancer research.

[37]  S. Stacker,et al.  The role of tumor lymphangiogenesis in metastatic spread , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[38]  K. Alitalo,et al.  Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. , 2002, Journal of the National Cancer Institute.

[39]  M. Karkkainen,et al.  Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. , 2001, Cancer research.

[40]  L. Orci,et al.  Vascular endothelial growth factor‐C‐mediated lymphangiogenesis promotes tumour metastasis , 2001, The EMBO journal.

[41]  Thomas Hawighorst,et al.  Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis , 2001, Nature Medicine.

[42]  D. Ribatti.  Antiangiogenic therapy accelerates tumor metastasis. , 2011, Leukemia research.

[43]  V. Preedy,et al.  Prospective Cohort Study , 2010 .